Zacks: Analysts Expect AnaptysBio Inc (ANAB) Will Announce Earnings of -$0.89 Per Share

Analysts predict that AnaptysBio Inc (NASDAQ:ANAB) will report ($0.89) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have made estimates for AnaptysBio’s earnings. The highest EPS estimate is ($0.81) and the lowest is ($0.96). AnaptysBio reported earnings of ($0.30) per share in the same quarter last year, which indicates a negative year over year growth rate of 196.7%. The company is scheduled to announce its next quarterly earnings report on Monday, March 4th.

Zacks’ EPS calculations are an average based on a survey of research analysts that cover AnaptysBio.

AnaptysBio (NASDAQ:ANAB) last released its earnings results on Thursday, November 8th. The biotechnology company reported ($0.66) earnings per share for the quarter, topping the consensus estimate of ($0.71) by $0.05. The firm had revenue of $5.00 million during the quarter.

A number of analysts have issued reports on the stock. Zacks Investment Research cut shares of AnaptysBio from a “hold” rating to a “sell” rating in a research note on Friday, November 9th. Cantor Fitzgerald set a $140.00 target price on shares of AnaptysBio and gave the company a “buy” rating in a research note on Monday. JPMorgan Chase & Co. assumed coverage on shares of AnaptysBio in a research note on Wednesday, November 21st. They issued an “overweight” rating and a $115.00 target price for the company. Royal Bank of Canada reiterated a “hold” rating and issued a $84.00 target price on shares of AnaptysBio in a research note on Wednesday, August 8th. Finally, JMP Securities reduced their target price on shares of AnaptysBio from $180.00 to $153.00 and set a “buy” rating for the company in a research note on Wednesday, August 15th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and nine have issued a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $129.09.

Several institutional investors have recently modified their holdings of the company. FMR LLC lifted its stake in shares of AnaptysBio by 11.7% in the third quarter. FMR LLC now owns 3,935,467 shares of the biotechnology company’s stock worth $392,642,000 after buying an additional 410,918 shares during the last quarter. Janus Henderson Group PLC increased its position in AnaptysBio by 11.1% during the third quarter. Janus Henderson Group PLC now owns 3,143,155 shares of the biotechnology company’s stock worth $313,592,000 after acquiring an additional 312,833 shares during the period. Vanguard Group Inc. increased its position in AnaptysBio by 20.0% during the third quarter. Vanguard Group Inc. now owns 1,851,930 shares of the biotechnology company’s stock worth $184,767,000 after acquiring an additional 308,517 shares during the period. BlackRock Inc. increased its position in AnaptysBio by 11.1% during the third quarter. BlackRock Inc. now owns 1,627,140 shares of the biotechnology company’s stock worth $162,341,000 after acquiring an additional 162,516 shares during the period. Finally, OppenheimerFunds Inc. increased its position in AnaptysBio by 5.2% during the second quarter. OppenheimerFunds Inc. now owns 1,101,887 shares of the biotechnology company’s stock worth $78,278,000 after acquiring an additional 54,773 shares during the period.

Shares of ANAB opened at $72.25 on Friday. The company has a market cap of $2.00 billion, a P/E ratio of -47.53 and a beta of 3.42. AnaptysBio has a 52 week low of $62.56 and a 52 week high of $134.00.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's proprietary anti-inflammatory pipeline includes ANB020, an anti-interleukin-33 antibody for the treatment of moderate-to-severe adult atopic dermatitis, severe adult peanut allergy, and severe adult eosinophilic asthma; ANB019, an anti-interleukin-36R antibody for the treatment of rare inflammatory diseases, including generalized pustular psoriasis and palmo-plantar pustular psoriasis; and a portfolio of checkpoint receptor agonist antibodies for the treatment of certain autoimmune diseases.

Read More: Earnings Per Share

Get a free copy of the Zacks research report on AnaptysBio (ANAB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AnaptysBio (NASDAQ:ANAB)

Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit